To the best of our knowledge, no reported studies evaluated whether the relationship between pre- and post-treatment serum AFP levels predict recurrent tumor size in HCC patients treated by hepatic resection (HR), transarterial chemoembolization (TACE), or radiofrequency ablation (RFA). Here, AFP is linked to hepatocellular carcinoma.